TGFB2 and gastrointestinal stromal tumor: Upon treating GIST cells with Wortmannin, an inhibitor of the PI3K-AKT signaling pathway, both the conditioned medium and recombinant TGF-β2 protein were unable to activate the PI3K-AKT signaling pathway in GIST cells (Fig. 5E, F).